SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as investors scrutinize the company's path to profitability and management's effectiveness ahead of its upcoming earnings report. The community remains deeply divided, with many debating the impact of the firm's voting structure and competitive headwinds while others highlight the potential for long-term growth through its AR glasses and subscription offerings.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is driving significant debate as it navigates volatility, with bulls highlighting the stock as a profitable machine characterized by exceptional margins and strong AI ad engine momentum, while skeptics point to a recent prospectus filing for a shelf offering as a potential catalyst for dilution. Investors are closely monitoring the stock's wide price swings and its ability to maintain growth, with many in the community debating whether the current price action is a temporary shakeout or a broader re-rating of software sector valuations.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is facing severe selling pressure after providing a weak full-year earnings outlook and citing recession-level demand for appliances in North America. The community is actively debating the stock's long-term viability, with many pointing to the dividend suspension as a catalyst for forced institutional selling while contrarian traders scout for a potential bottom.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as the community highlights recent strong revenue growth and debt repayment, fueling speculation about an imminent acquisition by a larger pharmaceutical player. Investors are closely tracking near-term catalysts, including potential European regulatory approval and patent extensions, while actively debating the valuation disconnect compared to similar recent biotech sector deals.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as traders anticipate key regulatory catalysts and evaluate the company's aggressive global expansion strategy for its cell therapy technology. The community is focused on the potential for a significant short squeeze, driven by heavy short interest and high expectations for upcoming clinical data, despite ongoing frustration regarding historical FDA interactions and market volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant momentum and bullish sentiment following the acquisition of Mirantis, a strategic move that provides a crucial software layer for its AI cloud infrastructure and positions the company to better compete with peers like Nebius. The stock is actively trending as investors monitor potential hyperscaler contract announcements ahead of upcoming earnings, with high call volume reflecting optimism that the company is successfully executing its pivot to a full-stack AI infrastructure provider.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending due to significant attention surrounding its recent release of preclinical data on ERNA-101, which reported complete tumor clearance and long-term survival in ovarian cancer models. The community remains deeply divided, with some investors highlighting the potential of the MD Anderson collaboration and high short interest, while skeptics warn of potential dilution traps and the limitations of preclinical mouse studies.

Agilon Health, Inc. engages in the provision of healthcare services. It also provides capital, data, payor relationships, executive experience, and contract support that allow physician groups to take on the risk of total care for their patients. The company was founded by Ronald A. Williams and Veeral Desai in 2016 and is headquartered in Westerville, OH.

Agilon Health Inc

Agilon Health is trending as investors digest a series of earnings reports and leadership transitions, with community sentiment split between those viewing the current valuation as a deep-value opportunity and those concerned about ongoing management performance and potential dilution. The conversation is heavily focused on the stock's high volatility, low float, and intense speculation regarding a possible takeover or fundamental turnaround under new leadership.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors weigh strong interim Phase 3 efficacy data and Best-in-Class potential against recent price volatility, while the community remains hyper-focused on upcoming 52-week trial results. Sentiment is divided between long-term bulls highlighting scientific superiority and potential M&A activity, and skeptical traders debating the timing of institutional catalysts.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing significant volatility as investors weigh strong quarterly growth and expansion plans against concerns over long-term margins and market valuation. The community remains deeply divided, with some pointing to persistent lines and high brand loyalty as reasons to buy on dips, while others warn of potential downside risks amid broader economic pressures and high historical share sales by insiders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Perceptive Advisors Llc Sells 31,810 Shares of Lyra Therapeutics (NASDAQ:LYRA) Stock

Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) major shareholder Perceptive Advisors Llc sold 31,810 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an...

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (NASDAQ:LYRA) Major Shareholder Perceptive Advisors Llc Sells 32,149 Shares

Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) major shareholder Perceptive Advisors Llc sold 32,149 shares of Lyra Therapeutics stock in a transaction on Thursday, November 6th. The shares...

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of +237.50% and +83.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dentsply International (XRAY) Lags Q3 Earnings Estimates

Dentsply (XRAY) delivered earnings and revenue surprises of -17.78% and +0.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an additional clinical trial for its lead product candidate for chronic rhinosinusitis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161569/0/en/Lyra-Therapeutics-Announces-Clinical-Plan-for-LYR-210-and-Late-Breaking-Oral-Presentation-of-Phase-3-ENLIGHTEN-2-Study.html">stated</a> that the U.S. Food and Drug Administration confirmed at a meeting in September that an additional trial was required for the submission of a new drug application for LYR-210 in the treatment of chronic rhinosinusitis without nasal polyps. The design of the new trial will be based on the learnings from previous trials, as well as feedback from the FDA, the company said."We look forward to continuing the development of LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management,” CEO Maria Palasis said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_06_at_2_16_16_PM_png_84207e66c2.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits</figcaption></figure>In June, Lyra announced positive results from a late-stage trial of LYR-210 in adult patients with CRS. It demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for the treatment of CRS.LYRA stock is down 19% this year and approximately 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">Why Did Spruce Biosciences Stock Quadruple Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

The company stated that the design of the new trial will be based on the learnings from the previous trials, in addition to FDA feedback.

Equity

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Lyra Therapeutics Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

LYRA
Lyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LYRA News

LYRALyra Therapeutics Inc